Leukemia, Myelodysplastic Syndromes
Conditions
Keywords
refractory cytopenia with multilineage dysplasia, childhood myelodysplastic syndromes, previously treated myelodysplastic syndromes, secondary myelodysplastic syndromes
Brief summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at blood samples in young patients with cytopenia after undergoing a donor stem cell transplant.
Detailed description
OBJECTIVES: Primary * To study hematopoietic chimerism in whole blood and different cell populations (i.e., CD14, CD15, CD 56, CD3, and CD19) as well as in dendritic cells and regulatory T cells after allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in patients with refractory cytopenia. * To compare the results of chimerism obtained with standard short tandem nucleotide polymorphism PCR (sensitivity 1%) with those obtained with single nucleotide polymorphisms PCR (sensitivity 0.1- 0.01%). Secondary * To evaluate the relationship between mixed chimerism and hematological engraftment, overall survival, and event-free survival. * To study the impact of mixed chimerism in plasmacytoid dendritic and regulatory T cells on the incidence of acute and chronic graft-versus-host-disease. OUTLINE: This is a multicenter study. Peripheral blood is collected from patients and donors prior to hematopoietic stem cell transplantation (HSCT). Patients also undergo blood sample collection on days 30, 60, 100, and 180 after transplantation. Peripheral blood cells are enriched and separated into lineage-specific subpopulations (i.e., CD3, CD14, CD15, CD19, and CD56) which are then divided equally for either DNA isolation via PCR or for flow cytometry. DNA concentrations in pre-HSCT donor and patient samples and in post-HSCT subpopulation samples are determined using quantitative real-time PCR. Samples are also analyzed for quantification of chimerism and detection of genetic markers via short tandem repeats- and sequence nucleotide polymorphism-based chimerism analyses.
Interventions
GENETICpolymerase chain reaction
OTHERflow cytometry
OTHERlaboratory biomarker analysis
PROCEDUREallogeneic hematopoietic stem cell transplantation
Sponsors
European Working Group of MDS in Childhood
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosed with refractory cytopenia * Hypocellular bone marrow and normal karyotype * Underwent stem cell transplantation (SCT) from an HLA identical (8/8) sibling, an HLA identical (10/10) relative, or an HLA identical or single allelic disparate unrelated donor * Received a preparative regimen including either thiotepa or fludarabine phosphate * Concurrently enrolled on EWOG-MDS-2006 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with complete chimerism as measured by standard short tandem nucleotide polymorphism PCR in whole blood and the different cell populations | — |
| Number of patients with complete chimerism as measured by single nucleotide polymorphisms PCR in the different cell populations | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with mixed chimerism and full hematological recovery at day 100 | — |
| Number of patients with mixed chimerism and acute or chronic graft-versus-host disease | — |
Countries
Austria, Belgium, Czechia, Denmark, Germany, Italy, Netherlands, Poland, Switzerland
Outcome results
None listed